The appropriate agreement has been signed at the Biprom-2024 International Forum

Photo: Bioprom press office

Rostec State Corporation will start producing the Russian nitroglycerin substance for medical applications. The appropriate agreement has been signed within the Biprom-2024 Forum. Production will be set up at one of Rostec’s facilities. Such active substances are not produced in Russia at this point.  

Nitroglycerin is included in the list of vital and essential drugs. It is used in myocardial infarction, coronary heart disease, stable angina and other heart diseases. Nitroglycerin is especially needed for acute disorders and emergency medical care. 

“There is still high need for such high quality drugs in Russia. Our production capacity will be 2 tons of medical-grade nitroglycerin per month, start of production will ensure independence on foreign supplies. The first batch of the domestic drug is to be dispatched to the customers in late 2025 — early 2026. The project launch specifications have been finished at this point,” said Sergey Tsyb, State Secretary of Rostec State Corporation. 

Nitroglycerin will be produced in accordance with the medical standard and high purity grade. 

The first International Forum ‘Bioprom: Industry and Technology for Humans’ is held in Gelendzhik on 7-8 October.